Post by Akribion Therapeutics

We’re proud to share a major milestone: Akribion Therapeutics core platform technology including first in-vivo data is now published in Nature.  Our programmable and proprietary nuclease G-dase® E, scientifically termed GeCas12a2 demonstrates a new approach for transcript-specific cell depletion of pathogenic mammalian cells.   This concept is simple but powerful: identify diseased cells based on their pathogenic RNA signature – and eliminate them selectively. We believe this can mark the beginning of a new way of thinking about disease treatment based on pathogenic sequence code errors.  This technology platform is now independently validated at the highest scientific level – and we’re just getting started to explore its potential beyond our lead indication in HPV positive head and neck cancer, across oncology as well as autoimmune, fibrotic and infectious diseases.   Encouraged by the strong interest from investors and both academic and industry partners, we are preparing for our upcoming Series A financing to advance to first-in-human studies and remain open to additional collaborations.   Congratulations to the whole Akribion Therapeutics team led by Paul Scholz as well as to our academic collaborators led by Chase Beisel, Ryan Jackson and Yang Liu. This achievement would not have been possible without your dedication and outstanding work!   https://lnkd.in/d_TrRE9M   Utah State University, University of Utah School of Medicine, Helmholtz Institute Würzburg (HIRI)  #Biotech #PrecisionMedicine #DrugDevelopment #CRISPR #FIH #RNA #NextGenTherapeutics #SeriesA #BiotechInvesting #DeepTech #AutoimmuneDisease #FibroticDiseases #InfectiousDiseases #Oncology